INCY Incyte Corporation

78.52
+1.06  (+1%)
Previous Close 77.46
Open 77.42
Price To Book 7.51
Market Cap 16,887,031,709
Shares 215,066,629
Volume 803,575
Short Ratio
Av. Daily Volume 1,135,124
Stock charts supplied by TradingView

NewsSee all news

  1. Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo

    - Data presented at EADV demonstrate continued improvement in repigmentation of vitiligo lesions upon longer treatment duration with ruxolitinib cream Incyte (NASDAQ:INCY) today announces positive 52-week results from

  2. Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress

    INDIANAPOLIS, Oct. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that it will present new data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 28th annual European

  3. Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma

    Data presented at ESMO support the planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pemigatinib before the end of 2019 Investor conference call and webcast

  4. Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

    Incyte (NASDAQ:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult

  5. Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

    Incyte (NASDAQ:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 BREEZE-AD7 trial met primary endpoint - August 23, 2019.
Baricitinib
Atopic dermatitis
NDA filing to be submitted 4Q 2019.
Pemigatinib (FIGHT-202)
Cholangiocarcinoma
Phase 2 interim data released at ASH 2018.
INCB54828 (FIGHT-203)
MPN (Myeloproliferative Neoplasms)
Phase 2 enrolment to be completed in 2019.
INCB54828 (FIGHT-201)
Bladder cancer
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Phase 1/2 enrolling.
Epacadostat with Keytruda - (ECHO-206)
Cancer - solid tumors
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line non-small cell lung cancer
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line head and neck cancer
Approved November 16, 2011.
Jakafi
Myelofibrosis
Phase 3 data due 2H 2019.
Itacitinib - GRAVITAS-301
Treatment-naïve acute GVHD
Phase 2 trial to be discontinued - noted June 21, 2018.
INCB50465 (CITADEL-202)
Diffuse large B cell lymphoma
Pivotal Phase 2 trial initiation announced November 15, 2017.
Ruxolitinib (RESET-272)
Essential thrombocythemia
Phase 3 data due 2H 2019.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 data due 2H 2019.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 3 planned.
Epacadostat with Keytruda
Squamous cell carcinoma of the head and neck cancer
Phase 3 planned.
Epacadostat with Keytruda
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
CRL received April 14, 2017. NDA resubmitted. Approval announced for low dose only - June 1, 2018.
Baricitinib
Rheumatoid arthritis
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Approved December 4, 2014.
Jakafi (ruxolitinib) (RESPONSE)
Polycythemia Vera
FDA approval announced May 24, 2019.
Ruxolitinib
Graft versus host disease
Phase 3 trial discontinued due to lack of efficacy
Ruxolitinib - JANUS 1 and JANUS 2
Cancer - Pancreatic
Phase 2 trial stopped January 2016 due to lack of efficacy
Ruxolitinib
Colorectal cancer
Endpoint not met, mid-2014
Jakafi (ruxolitinib) (RELIEF)
Disease-related symptoms in patients with Polycythemia Vera
Phase 3 trial to commence 1H 2018.
Epacadostat with durvalumab
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-303)
Bladder cancer
NDA filing due 2019.
INC280
Non-small cell lung cancer
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-307)
Bladder cancer
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-304)
Head & neck cancer
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-309)
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-310)
Head and neck cancer
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-306)
Non-small cell lung cancer (NSCLC)
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-305)
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-302)
Renal cancer
Phase 1 oral abstract June 1, 2018, 2:45p.m. CT. Abstract 8005.
Ruxolitinib, Lenalidomide, and Methylprednisolone
Relapsed/Refractory Multiple Myeloma
Phase 1/2 ongoing.
INCB024360 + Epacadostat
Solid tumors
Phase 3 initial data due 1H 2020.
Ruxolitinib
Atopic dermatitis
Phase 2 initial data due 2020.
Parsaclisib INCB50465 (CITADEL-203)
Follicular lymphoma
Phase 2 initial data due 2020.
Parsaclisib INCB50465 (CITADEL-204)
Marginal zone lymphoma
Phase 2 initial data due 2020.
Parsaclisib INCB50465 (CITADEL-205)
Mantle cell lymphoma
Phase 1 data due 2021.
INCMGA0012
Anal cancer
Phase 1 poster presentation at AACR April 1, 2019.
INCMGA0012
Solid tumors
Phase 1 initial data due 2020.
INCMGA0012
Endometrial cancer
Phase 2 data presented at ASH December 2, 2018.
INCB50465 and ruxolitinib
Myelofibrosis
Phase 3 commencement of dosing announced September 25, 2019.
Ruxolitinib - TRuE-V
Vitiligo
Phase 2 top-line data due 2H 2019.
DPX-Survivac and epacadostat (DeCidE1)
Ovarian cancer
Phase 1/2 data at ESMO 2019 noted - 7% PR rate.
INCB001158
Solid tumors
Phase 3 data due 2020.
Baricitinib
Alopecia Areata
Phase 3 data due 2021.
Baricitinib
Systemic lupus erythematosus (SLE)
Phase 3 commencement of dosing announced January 22, 2019.
Itacitinib - GRAVITAS-309
Chronic Graft-Versus-Host Disease
Phase 3 initiation of dosing announced June 4, 2019.
Pemigatinib (FIGHT-302)
Cholangiocarcinoma - first line

Latest News

  1. Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo

    - Data presented at EADV demonstrate continued improvement in repigmentation of vitiligo lesions upon longer treatment duration with ruxolitinib cream Incyte (NASDAQ:INCY) today announces positive 52-week results from

  2. Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress

    INDIANAPOLIS, Oct. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that it will present new data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 28th annual European

  3. Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma

    Data presented at ESMO support the planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pemigatinib before the end of 2019 Investor conference call and webcast

  4. Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

    Incyte (NASDAQ:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult

  5. Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

    Incyte (NASDAQ:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult

  6. Incyte to Host Investor Conference Call from ESMO 2019

    Incyte (NASDAQ:INCY) announced today that it will host a conference call and webcast Friday, September 27, 2019, at 11:00 a.m. EDT (5:00 p.m. CEST), to discuss updated pemigatinib data presented at the European Society

  7. BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia

    BERKELEY, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  8. BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49

    BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  9. Incyte Launches #MyMPNChallenge to Inspire the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month

    Social media campaign designed to spark MPN conversations and increase awareness and education about MPNs, a group of rare, chronic blood cancers, launches today To further support the MPN community, for every

  10. Incyte Launches #MyMPNChallenge to Inspire the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month

    Social media campaign designed to spark MPN conversations and increase awareness and education about MPNs, a group of rare, chronic blood cancers, launches today To further support the MPN community, for every

  11. Data from Incyte's Oncology Portfolio to be Featured at the 2019 ESMO Congress

    Updated Phase 2 results from the FIGHT-202 study highlight the potential of pemigatinib as a treatment option for patients with previously treated, advanced cholangiocarcinoma Incyte (NASDAQ:INCY) announces that

  12. BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019

    BERKELEY, Calif. and VANCOUVER, British Columbia, Aug. 27, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  13. Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis

    INDIANAPOLIS, Aug. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial

  14. Incyte to Present at Upcoming Investor Conferences

    Incyte Corporation (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of September: Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September